Sale to Halma plc

Healthcare
Sale to Halma plc

Summary

Baird served as exclusive financial advisor to NovaBone Products, LLC on this transaction

About

NovaBone Products, LLC (“NovaBone” or the “Company”) was recently acquired by Halma plc (“Halma”) (LSE: HLMA) for a total purchase price of $137 million, including $97 million of cash at closing and additional contingent earn-out considerations of up to $40 million in cash based on achieving certain profit growth targets.

NovaBone was established in 2002 with a focus on developing biomaterials that harness the body’s natural healing process while meeting the needs of orthopedic and dental surgeons. NovaBone offers a broad portfolio of regenerative biologics that include bone formation products, as well as products that repair and remodel tissue. NovaBone’s bone graft substitutes and collagen matrix devices have been used for nearly two decades in millions of clinical applications. NovaBone is headquartered in Jacksonville, Florida.

Halma is a global group of life-saving technology companies, focused on creating a safer, cleaner and healthier future for people worldwide. Halma’s innovative products and solutions address many of the key issues facing the world today with a focus on four sectors: Process Safety, Infrastructure Safety, Environmental & Analysis, and Medical. Halma targets global niche markets where sustainable growth and high returns are supported by long-term drivers. Halma employs over 6,000 people in 20 countries and is headquartered in Amersham, the United Kingdom.
CONTACT US TO LEARN MORE
Healthcare
Sale to Halma plc
Date
January 2020
Company
NovaBone Products, LLC
Transaction
M&A
Sectors
Healthcare
Target Location
North America
Acquiror Location
Europe

Share